Helping obese people and diabetics
Hung Mien-chie, president of Taiwan’s China Medical University, noted at the 2024 Tang Prize Masters’ Forums that the forward-looking research of the Biopharmaceutical Science Prize laureates has made outstanding contributions to the control of type 2 diabetes and obesity, benefiting the 500 million diabetes sufferers and nearly 1 billion obese people worldwide.
Joel F. Habener and Svetlana Mojsov, then colleagues in the Endocrine Unit at Massachusetts General Hospital, synthesized GLP-1 (7–37)—a truncated form of glucagon-like peptide-1 (GLP-1)—and identified it as a bioactive hormone that can stimulate insulin secretion. This important discovery redefined the long-sought-after “incretin” (an intestine-secreted hormone that triggers insulin release), and they proved that GLP-1 (7–37) has the potential to treat type 2 diabetes and to be used in diabetes prevention.
Meanwhile, in faraway Denmark, Jens Juul Holst of the University of Copenhagen independently isolated GLP-1 (1–37) and GLP–1 (7–36) amide, and successfully identified the latter as an active incretin with superior functions in terms of reducing blood sugar as well as suppressing glucagon, peristalsis, and appetite.
Whether it be the contributions to human health made by the three winners of the Tang Prize in Biopharmaceutical Science, Omar Yaghi’s advocacy of a philosophy of life that overcomes the obstacles in one’s environment, or the rebuilding of public trust in the rule of law emphasized by Mary Robinson, the winners of the sixth Tang Prizes all are working to find sustainable, peaceful, and healthy ways forward for today’s confused and confusing world.